Advances in childhood vasculitis

被引:19
作者
Eleftheriou, Despina [1 ,3 ]
Dillon, Michael J. [2 ,4 ]
Brogan, Paul A. [1 ,3 ]
机构
[1] Inst Child Hlth, Dept Paediat Rheumatol, London WC1N 1EH, England
[2] Inst Child Hlth, Dept Paediat Nephrol, London WC1N 1EH, England
[3] Great Ormond St Hosp Sick Children, Dept Paediat Rheumatol, London WC1N 1EH, England
[4] Great Ormond St Hosp Sick Children, Dept Paediat Nephrol, London WC1N 1EH, England
关键词
biologic therapy; child; genetic polymorphisms; Henoch-Schonlein purpura; Kawasaki disease; vasculitis; HENOCH-SCHONLEIN PURPURA; SYSTEMIC NECROTIZING VASCULITIS; PLACEBO-CONTROLLED TRIAL; KAWASAKI-DISEASE; TAKAYASUS-ARTERITIS; INFLIXIMAB TREATMENT; GENE POLYMORPHISMS; CLINICAL-FEATURES; RANDOMIZED-TRIAL; BEHCETS-DISEASE;
D O I
10.1097/BOR.0b013e32832c49f2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review To provide an update on new developments in paediatric vasculitis. Recent findings New classification criteria for childhood vasculitis have recently been proposed and are currently undergoing validation. Infectious triggers are still implicated in the aetiopathogenesis of Kawasaki disease and Henoch-Schonlein purpura. Several genetic polymorphisms in vasculitides have now been described that may be relevant in terms of disease predisposition or development of disease complications. Treatment regimens continue to improve, with the use of different immunosuppressive medications and newer therapeutic approaches such as biologic agents. However, new challenges are looming with regard to the role of inflammation in endothelial health and the long-term cardiovascular morbidity for children with primary systemic vasculitis. Summary As our understanding of disease pathogenesis in vasculitis of the young has advanced, novel therapeutic approaches have been adapted. International multicentre collaboration is of great importance to further increase and standardize the scientific base of investigating and treating childhood vasculitis.
引用
收藏
页码:411 / 418
页数:8
相关论文
共 101 条
[1]   Clinical features and outcome of pediatric Wegener's granulomatosis [J].
Akikusa, J. D. ;
Schneider, R. ;
Harvey, E. A. ;
Hebert, D. ;
Thorner, P. S. ;
Laxer, R. M. ;
Silverman, E. D. .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (05) :837-844
[2]  
Amoli MM, 2002, J RHEUMATOL, V29, P1404
[3]  
Axel L, 1986, Magn Reson Annu, P237
[4]   Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? [J].
Beimler, JHM ;
Andrassy, K .
PEDIATRIC NEPHROLOGY, 2004, 19 (09) :949-955
[5]   Clinical features in 17 paediatric patients with Wegener granulomatosis [J].
Belostotsky, VM ;
Shah, V ;
Dillon, MJ .
PEDIATRIC NEPHROLOGY, 2002, 17 (09) :754-761
[6]   Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis [J].
Booth, A ;
Harper, L ;
Hammad, T ;
Bacon, P ;
Griffith, M ;
Levy, J ;
Savage, C ;
Pusey, C ;
Jayne, D .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (03) :717-721
[7]   Renal vasculitis - an update in 2004 [J].
Booth, AD ;
Pusey, CD ;
Jayne, DR .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (08) :1964-1968
[8]   Vasculitis from the pediatric perspective [J].
Brogan P.A. ;
Dillon M.J. .
Current Rheumatology Reports, 2000, 2 (5) :411-416
[9]   Renal angiography in children with polyarteritis nodosa [J].
Brogan, PA ;
Davies, R ;
Gordon, I ;
Dillon, MJ .
PEDIATRIC NEPHROLOGY, 2002, 17 (04) :277-283
[10]   Endothelial and platelet microparticles in vasculitis of the young [J].
Brogan, PA ;
Shah, V ;
Brachet, C ;
Harnden, A ;
Mant, D ;
Klein, N ;
Dillon, MJ .
ARTHRITIS AND RHEUMATISM, 2004, 50 (03) :927-936